Maintenance Durvalumab after First-Line Chemotherapy in Patients with HER2-negative Advanced Oesophago-Gastric Adenocarcinoma: Results from the Randomised PLATFORM Study
ESMO Open(2024)
Key words
durvalumab,checkpoint inhibitor,oesophageal adenocarcinoma,gastric cancer,maintenance therapy
AI Read Science
Must-Reading Tree
Example

Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined